Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

Legacy Context of General Health and Science Information

The legacy context of general health and science information has long served as a foundation for public understanding of medical conditions and therapeutic interventions. Within this broad framework, discussions of bone health and pharmaceutical treatments have been standard, with an emphasis on patient education and informed consent. As this heritage evolves, a natural progression emerges toward examining specific exposure scenarios that arise from widespread medication use. One such area of focus involves the relationship between bisphosphonate therapies, commonly prescribed for osteoporosis, and reports of adverse outcomes affecting the jaw. This pivot from general health discourse to a more targeted occupational concern is driven by the need to understand how routine clinical exposure to such medications may translate into risk for certain patient populations. The transition requires careful consideration of the pharmacological context without delving into mechanistic details, instead maintaining a neutral observation of the documented associations. By moving from broad health literacy to the specific question of drug exposure and its potential consequences, the discussion now centers on the practical implications for those who have received these treatments. This shift acknowledges the importance of monitoring and risk communication in clinical settings, while preserving the academic tone appropriate for scientific inquiry.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the legacy of general health information, we now focus specifically on Fosamax (alendronate), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence, including hip and spine fractures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a serious adverse effect associated with bisphosphonates, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often occurring spontaneously but generally associated with tooth extraction or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical presentation typically involves pain, swelling, infection, and exposed bone that fails to heal after dental procedures. Diagnosis relies on clinical examination and imaging, with a history of bisphosphonate use being a key consideration. The condition has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56) and Fosamax Plus D (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Preclinical Evidence

The mechanistic pathways linking Fosamax to ONJ are not fully understood but involve the drug's potent inhibition of osteoclast activity, which suppresses bone turnover. This suppression can impair the jawbone's ability to repair microdamage and respond to local stressors such as dental procedures or infection. Multiscale characterization of jawbone in animal models treated with bisphosphonates, including alendronate (the active ingredient in Fosamax), has provided insights into jawbone-specific responses. Studies using estrogen-deficient rats treated with alendronate have examined effects on jawbone tissue mineral density distribution, nanoindentation properties, and mechanical stability of teeth in the alveolar socket (https://pubmed.ncbi.nlm.nih.gov/40345077/). These findings help understand how bisphosphonate therapy may alter jawbone structure and function, potentially predisposing to ONJ.

Risk Factors and Clinical Considerations

Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific warning under section 5.4 titled "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Similarly, the label for Fosamax Plus D contains an identical warning (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings describe the association with dental procedures and infection, list known risk factors, and note that risk may increase with duration of exposure. However, the warnings do not provide specific incidence rates or detailed guidance on monitoring for ONJ in asymptomatic patients.

Causation Evidence and Temporal Relationship

For affected patients, causation considerations involve evaluating the temporal relationship between Fosamax exposure and ONJ onset, excluding other causes such as cancer, radiation therapy, or other medications. The timeline between exposure and documented harm can range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, but a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This pattern supports a causal relationship, as symptoms improve upon discontinuation and recur upon re-exposure. However, ONJ can also occur spontaneously without bisphosphonate use, complicating individual causation assessments. In summary, scientific evidence from FDA-approved labeling and preclinical studies establishes a connection between Fosamax and ONJ, with plausible mechanistic pathways involving suppressed bone turnover. Warnings in the prescribing information adequately describe the association and risk factors, though they lack detailed incidence data. For patients, the timeline of symptom onset and response to drug discontinuation provide important clues for causation, but individual cases require careful evaluation of all contributing factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence connecting Fosamax to osteonecrosis of the jaw?

Scientific evidence includes FDA-approved labeling that reports ONJ in patients taking Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56) and preclinical studies showing jawbone-specific changes in animal models treated with alendronate (https://pubmed.ncbi.nlm.nih.gov/40345077/). The mechanism involves suppressed bone turnover due to osteoclast inhibition, impairing jawbone repair.

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures, and longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is causation between Fosamax and ONJ determined in individual cases?

Causation is assessed by evaluating the temporal relationship between Fosamax exposure and ONJ onset (ranging from one day to several months), excluding other causes, and observing symptom improvement upon drug discontinuation and recurrence upon rechallenge (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.